Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State

被引:4
作者
Aquilani, Roberto [1 ]
Brugnatelli, Silvia [2 ]
Maestri, Roberto [3 ]
Boschi, Federica [4 ]
Filippi, Beatrice [2 ]
Perrone, Lorenzo [2 ]
Barbieri, Annalisa [4 ]
Buonocore, Daniela [1 ]
Dossena, Maurizia [1 ]
Verri, Manuela [1 ]
机构
[1] Univ Pavia, Dept Biol & Biotechnol Lazzaro Spallanzani, I-27100 Pavia, Italy
[2] Fdn IRCCS, Policlin San Matteo, Med Oncol Div, I-27100 Pavia, Italy
[3] Ist Clin Sci Maugeri IRCCS, Dept Biomed Engn, Montescano Inst, I-27040 Montescano, Italy
[4] Univ Pavia, Dept Drug Sci, I-27100 Pavia, Italy
关键词
advanced pancreatic cancer; impaired adaptive immune response; chemotolerance; survival; nutritional status; DUCTAL ADENOCARCINOMA; T-CELLS; RATIO; IMMUNOSURVEILLANCE; INFLAMMATION; PLATELET; MECHANISMS; STRATEGIES; PROGNOSIS; RESECTION;
D O I
10.3390/curroncol28050285
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Alterations of the immune system that consist of induced inflammation and reduction in blood lymphocytes are a major factor contributing to cancer progression in patients with pancreatic carcinoma (PC). Identification of the percentage of lymphocytes in the Total number of White Blood Cells (L% TWBC) that could be associated with chemotolerance and survival time may be important for predicting treatment efficacy. The aim of this retrospective study was to highlight the best value of L% for predicting chemotolerance (n & DEG; of cycles tolerated) and survival beyond 12 months from diagnosis. The study found that L & GE; 29.7% TWBC compared to L < 29.7% predicted chemotolerance (p < 0.0001) and survival at every time point of follow-up: 6 (p = 0.04), 12 (p = 0.0003) and 18 months (p = 0.004) after diagnosis. Simple, rapid, routine laboratory data can be useful to predict treatment tolerance and efficacy in PC patients.<br></p> <br></p> Pancreatic Carcinoma (PC) cells have the ability to induce patient immunosuppression and to escape immunosurveillance. Low circulating lymphocytes are associated with an advanced stage of PC and reduced survival. Blood lymphocytes expressed as a percentage of Total White Blood Cells (L% TWBC) could predict chemotolerance (n & DEG; of tolerated cycles), survival time and Body Weight (BW) more effectively than lymphocytes expressed as an absolute value (L-AB > 1500 n & DEG;/mm(3)) or lymphocytes > 22%, which is the lowest limit of normal values in our laboratory. Forty-one patients with advanced PC, treated with chemotherapy, were selected for this observational retrospective study. Patients were evaluated at baseline (pre-chemotherapy), and at 6, 12 and 18 months, respectively, after diagnosis of PC. The study found L & GE; 29.7% to be a better predictor of survival (COX model, using age, sex, BW, serum creatinine, bilirubin and lymphocytes as covariates), chemotolerance (r = +0.50, p = 0.001) and BW (r = +0.35, p = 0.027) than L-AB > 1500 or L > 22%. BW did not significantly correlate with chemotolerance or survival. The preliminary results of this study suggest that L & GE; 29.7% is more effective than L-AB > 1500 or L > 22% at predicting chemotolerance, survival time and nutritional status. A possible impact of nutritional status on chemotherapy and survival seems to be lymphocyte-mediated given the association between BW and L%. This study may serve as the basis for future research to explore whether nutritional interventions can improve lymphopenia, and if so, how this may be possible.</p>
引用
收藏
页码:3280 / 3296
页数:17
相关论文
共 47 条
  • [1] Immune responses in cancer
    Adam, JK
    Odhav, B
    Bhoola, KD
    [J]. PHARMACOLOGY & THERAPEUTICS, 2003, 99 (01) : 113 - 132
  • [2] Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
    Ahmad, M
    Rees, RC
    Ali, SA
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) : 844 - 854
  • [3] Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study
    Aquilani, Roberto
    Brugnatelli, Silvia
    Dossena, Maurizia
    Maestri, Roberto
    Delfanti, Sara
    Buonocore, Daniela
    Boschi, Federica
    Simeti, Elena
    Condino, Anna Maria
    Verri, Manuela
    [J]. NUTRIENTS, 2019, 11 (11)
  • [4] The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels A Retrospective Multicenter Cohort Study
    Aziz, Mohammad Hosein
    Sideras, Kostandinos
    Aziz, Nasir Ahmad
    Mauff, Katya
    Haen, Roel
    Roos, Daphne
    Saida, Lawlaw
    Suker, Mustafa
    van der Harst, Erwin
    Mieog, Jan Sven
    Bonsing, Bert A.
    Klaver, Yarne
    Koerkamp, Bas Groot
    van Eijck, Casper H.
    [J]. ANNALS OF SURGERY, 2019, 270 (01) : 139 - 146
  • [5] Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis
    Bhalla, Manav
    Aldakkak, Mohammed
    Kulkarni, Naveen M.
    O'Connor, Stacy D.
    Griffin, Michael O., Jr.
    Christians, Kathleen K.
    Evans, Douglas B.
    Tsai, Susan
    Tolat, Parag P.
    [J]. ABDOMINAL RADIOLOGY, 2018, 43 (02) : 351 - 363
  • [6] Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis
    Cheng, Liang
    Qin, Tao
    Ma, Jiguang
    Duan, Wanxing
    Xu, Qinhong
    Li, Xuqi
    Han, Liang
    Li, Wei
    Wang, Zheng
    Zhang, Dong
    Ma, Qingyong
    Lei, Jianjun
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (12) : 1503 - 1512
  • [7] Crocetti E, 2016, EPIDEMIOL PREV, V40, P28
  • [8] The immunobiology of cancer immunosurveillance and immunoediting
    Dunn, GP
    Old, LJ
    Schreiber, RD
    [J]. IMMUNITY, 2004, 21 (02) : 137 - 148
  • [9] Cancer immunoediting: from immunosurveillance to tumor escape
    Dunn, GP
    Bruce, AT
    Ikeda, H
    Old, LJ
    Schreiber, RD
    [J]. NATURE IMMUNOLOGY, 2002, 3 (11) : 991 - 998
  • [10] Metastatic pancreatic cancer: Emerging strategies in chemotherapy and palliative care
    El Kamar, FG
    Grossbard, ML
    Kozuch, PS
    [J]. ONCOLOGIST, 2003, 8 (01) : 18 - 34